Results 21 to 30 of about 3,596,940 (207)

Comparison of clinicopathologic characteristics, epigenetic biomarkers and prognosis between renal pelvic and ureteral tumors in upper tract urothelial carcinoma

open access: yesBMC Urology, 2018
Background There's no consensus about the difference between renal pelvic and ureteral tumors in terms of clinical features, pathological outcomes, epigenetic biomarkers and prognosis.
Dong Fang   +7 more
doaj   +1 more source

A Case of Renal Pelvic Cancer with a Complete Duplication of the Renal Pelvis and Ureter

open access: yesCase Reports in Oncology, 2021
This paper describes a case of renal pelvic cancer with a complete duplication of the renal pelvis and ureter, which is substantially rare. A 76-year-old man was referred to the hospital because of gross hematuria for 2 years. A tumor was detected in the
Takuma Nirei   +3 more
doaj   +1 more source

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer [PDF]

open access: yes, 2008
Background Enhanced activity of histone deacetylases (HDAC) is associated with more aggressive tumour behaviour and tumour progression in various solid tumours.
Dietel Manfred   +21 more
core   +1 more source

Ultrasound scanning in fetal renal pelvis dilatation: not only hydronephrosis [PDF]

open access: yes, 2009
Pelvic dilatation is the alteration of the urinary tractmost frequently detected by maternal-fetalultra-sound. Hydronephrosis is not a diagnosis; it is an imagefinding. The diagnosis is the cause that produces it.
Dinatale, Angela   +6 more
core   +1 more source

Renal pelvic urothelial carcinoma with imaging features presenting as renal infarction 1 case report and literature review

open access: yesUrology Case Reports
Renal pelvic cancer is relatively rare in clinical practice, and renal pelvic cancer characterized by renal infarction is even rarer. We here report a case of renal pelvic urothelial carcinoma with squamous metaplasia with renal infarction as the main ...
Haidong Yang   +7 more
doaj   +1 more source

Radical Cystectomy and Lymphadenectomy to Two Patients with Pelvic Kidney: Surgical Pitfalls and Considerations

open access: yesCase Reports in Medicine, 2013
Our goal is to describe our experience in the difficulties encountered during radical cystectomy for muscle invasive bladder cancer in patients with contemporary pelvic kidney.
I. Adamakis   +8 more
doaj   +1 more source

Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis

open access: yeseNeurologicalSci, 2020
Pembrolizumab is an immune checkpoint inhibitor (ICI) that targets the programmed cell death (PD)-1 receptor. It significantly increases the overall survival in patients with locally advanced or metastatic urothelial cancer.
Akiko Ishii   +4 more
doaj   +1 more source

3D laparoscopic treatment of bladder cancer with pelvic multi-organ invasion: a case report and literature review

open access: yesFrontiers in Oncology, 2023
IntroductionRadical cystectomy with dissection of pelvic lymph nodes and urethral diversion is the standard surgical treatment for muscle-invasive non-metastatic bladder cancer.
Zheng Chen   +9 more
doaj   +1 more source

Total Infralevatorian Exenteration with Vulvectomy as Salvage Therapy in a Recurrent Irradiated Cervical Cancer with Pelvic Sidewall Involvement

open access: yesJournal of Interdisciplinary Medicine, 2017
Despite the available effective screening techniques, cervical cancer is the most common genital malignancy in Romania. In patients with isolated pelvic recurrence after radiotherapy, exenteration represents the only chance for curative treatment.
Bécsi János   +3 more
doaj   +1 more source

Pancreatitis as immune‐related adverse event during pembrolizumab therapy for multiple lung metastases from renal pelvic cancer

open access: yesIJU Case Reports, 2023
Introduction Pembrolizumab administration has become the standard of care for patients with urothelial carcinoma, though a variety of adverse events have been reported.
Kazuki Kokura   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy